Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT05866575 Not yet recruiting - Clinical trials for Major Depressive Disorder

Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation

STRATIDEP
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This study aims to better understand the mechanisms of action of antidepressants, but also the neural correlates of motivation deficits. One hundred patients with a moderate to severe major depressive episode will be enrolled in this prospective multicenter study. The objective will be to predict the therapeutic response to two first-line antidepressants on the basis of an early neurocomputational assessment of motivation. Antidepressant treatment will be administered as monotherapy after randomization between two drugs: escitalopram and vortioxetine. Patients will undergo six visits and follow-up for one year. The investigators will combine computer modeling and functional MRI to identify motivational deficits and elucidate their brain correlates before initiation, after 7 days and after 6 months of treatment. 36 healthy volunteers will also be included to allow comparison with patients with depression. They will not receive any treatment.

NCT ID: NCT05812001 Not yet recruiting - Clinical trials for Major Depressive Disorder

Exergames-acceptance and Commitment Therapy Program for Treatment of Major Depressive Disorder

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Background: The prevalence of depressive disorder, particularly major depressive disorder is on the rise globally and the use of antidepressant medication for treatment does not usually resulting in full remission. However, combination of antidepressant medication and psychotherapy for treatment of major depressive disorder (MDD) increase the rate of full remission compared to antidepressant monotherapy. This three-armed, parallel-group, double-blind, randomized control trial (RCT) aims to assess and compare the effects of combination of exergame and acceptance and commitment (e-ACT) training programme and ACT only on psychiatric symptoms (depression and anxiety), experiential avoidance (EA), quality of life (QoL), and biomarkers of depression (such as BDNF, CRP, and VEGF) among MDD patients. Methods: This RCT will recruit 120 patients diagnosed with MDD who will be randomized using stratified permuted block randomization into three groups, which are combined e-ACT training programme, ACT only and treatment-as-usual control groups in a 1:1:1 allocation ratio. The participants in the e-ACT and ACT only intervention groups will undergo once a week intervention sessions for 8 weeks. Assessments will be carried out through three time points, such as the first assessment before intervention began (t0), second assessment immediately after completion of intervention at 8 weeks (t1) and third assessment 24 weeks after completion of intervention (t2). During each assessment, the primary outcome assessed is the severity of depression symptoms, while the secondary outcomes assessed are severity of anxiety symptoms, QoL, EA, and biomarkers of depression.

NCT ID: NCT05785312 Not yet recruiting - Clinical trials for Major Depressive Disorder

Development of Online EMDR Therapy System and Its Comparative Testing With Face-to-Face EMDR Therapy for Treatment of Anxiety and Depressive Disorders in Pakistan

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study aims at developing an online system for the remote delivery of EMDR therapy in Pakistan. Moreover, this study will compare the efficacy of online EMDR therapy with face-to-face EMDR therapy.

NCT ID: NCT05762458 Not yet recruiting - Clinical trials for Major Depressive Disorder (MDD)

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Ammoxetine
Start date: February 28, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

NCT ID: NCT05725785 Not yet recruiting - Schizophrenia Clinical Trials

Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about how a digital training platform can enhance implementation and effectiveness of a validated mHealth system, called FOCUS, in people with serious mental illness. The main question this research aims to answer is whether patients obtain similar outcomes to previous FOCUS studies when using FOCUS with clinicians trained on a newly developed digital training platform. Participants will be asked to use the FOCUS smartphone application and receive mobile health coaching from clinicians who have been trained using the digital training platform.

NCT ID: NCT05710887 Not yet recruiting - Clinical trials for Major Depressive Disorder

N2O for Acute Suicidality and Depression in the ED

Start date: October 1, 2024
Phase: Phase 2
Study type: Interventional

Investigators are conducting this double-blind, randomized control trial (RCT), to compare inhaled N2O+ treatment as usual (TAU) versus inhaled placebo+TAU; demonstrating the feasibility and tolerability of the intervention in an emergency department (ED) setting on an acutely suicidal population.

NCT ID: NCT05707299 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Effect of Intradermal Acupuncture on Gallbladder Meridian Points on Cerebral Hemodynamics in Relevant Brain Regions for Major Depressive Disorder Based on fNIRS Technology

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Gallbladder meridian(GB) acupoints may play an important role in the treatment of major depressive disorder (MDD). Therefore, this study is designed to focus on the traditional Chinese medicine (TCM) theory of " gallbladder dominating decision ", take the GB as the entry point, and use functional Near-Infrared Spectroscopy(fNIRS) technology to observe the effect of intradermal acupuncture on the cerebral hemodynamic indexes of the prefrontal cortex and bilateral temporal cortex of patients with MDD.

NCT ID: NCT05675800 Not yet recruiting - Clinical trials for Major Depressive Disorder

Psilocybin for Major Depressive Disorder

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to assess the effectiveness of psilocybin for the treatment of Major Depressive Disorder and potential therapeutic mechanisms. Enrolled participants will receive a single active dose of psilocybin, or a dose considered high enough to treat depression, administered orally with accompanying psychological support.

NCT ID: NCT05649293 Not yet recruiting - Clinical trials for Vitamin b6 Level & Depression

Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder

Start date: April 1, 2023
Phase:
Study type: Observational

Estimation of vitamin B 6 levels in diagnosed major depressive disorder patients and their relation to the severity of the disease

NCT ID: NCT05644301 Not yet recruiting - Clinical trials for Major Depressive Disorder

INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

INSTA-MD
Start date: January 2023
Phase: Phase 3
Study type: Interventional

This is a randomised, double-blind, placebo-controlled clinical trial in which patients with major depressive disorder will receive augmentation through minocycline (MCO), celecoxib (CXB) or placebo.